Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
Eledon Pharmaceuticals (Nasdaq: ELDN) has announced its participation in the upcoming Leerink Partners Global Healthcare Conference. The company's Chief Scientific Officer and President, Steve Perrin, Ph.D., will engage in a fireside chat scheduled for Tuesday, March 11, 2025, at 2:20 p.m. ET (11:20 a.m. PT).
Interested parties can register in advance for the webcast of the fireside chat. Following the live session, a replay will be made available on the Company's website under the Events section.
Eledon Pharmaceuticals (Nasdaq: ELDN) ha annunciato la sua partecipazione alla prossima Conferenza Globale sulla Salute di Leerink Partners. Il Chief Scientific Officer e Presidente dell'azienda, Steve Perrin, Ph.D., parteciperà a una chiacchierata informale programmata per martedì 11 marzo 2025, alle 14:20 ET (11:20 PT).
Le parti interessate possono registrarsi in anticipo per la trasmissione in diretta della chiacchierata informale. Dopo la sessione dal vivo, una registrazione sarà disponibile sul sito web dell'azienda nella sezione Eventi.
Eledon Pharmaceuticals (Nasdaq: ELDN) ha anunciado su participación en la próxima Conferencia Global de Salud de Leerink Partners. El Director Científico y Presidente de la compañía, Steve Perrin, Ph.D., participará en una charla informal programada para el martes 11 de marzo de 2025, a las 2:20 p.m. ET (11:20 a.m. PT).
Las partes interesadas pueden registrarse con anticipación para la transmisión en vivo de la charla. Después de la sesión en vivo, se pondrá a disposición una repetición en el sitio web de la compañía en la sección de Eventos.
Eledon Pharmaceuticals (Nasdaq: ELDN)는 다가오는 Leerink Partners 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 최고 과학 책임자이자 사장인 Steve Perrin, Ph.D.는 2025년 3월 11일 화요일 오후 2시 20분 ET (오전 11시 20분 PT)로 예정된 파이어사이드 챗에 참여할 예정입니다.
관심 있는 당사자는 파이어사이드 챗의 웹캐스트에 사전 등록할 수 있습니다. 라이브 세션 후에는 회사 웹사이트의 이벤트 섹션에서 다시 보기를 이용할 수 있습니다.
Eledon Pharmaceuticals (Nasdaq: ELDN) a annoncé sa participation à la prochaine Conférence Mondiale sur la Santé de Leerink Partners. Le Directeur Scientifique et Président de l'entreprise, Steve Perrin, Ph.D., participera à une discussion informelle prévue pour mardi 11 mars 2025, à 14h20 ET (11h20 PT).
Les parties intéressées peuvent s'inscrire à l'avance pour le webcast de la discussion. Après la session en direct, un enregistrement sera disponible sur le site Web de l'entreprise dans la section Événements.
Eledon Pharmaceuticals (Nasdaq: ELDN) hat seine Teilnahme an der bevorstehenden Leerink Partners Global Healthcare Conference bekannt gegeben. Der Chief Scientific Officer und Präsident des Unternehmens, Steve Perrin, Ph.D., wird an einem Fireside-Chat teilnehmen, der für Dienstag, den 11. März 2025, um 14:20 Uhr ET (11:20 Uhr PT) angesetzt ist.
Interessierte Parteien können sich im Voraus für die Webcast-Übertragung des Fireside-Chats registrieren. Nach der Live-Sitzung wird eine Wiederholung auf der Unternehmenswebsite im Bereich Veranstaltungen verfügbar sein.
- None.
- None.
IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 2:20 p.m. ET (11:20 a.m. PT).
To register in advance for the fireside chat webcast, sign up here.
A webcast replay will be accessible following the live session on the Company’s website under Events.
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com
Source: Eledon Pharmaceuticals
FAQ
When is Eledon Pharmaceuticals (ELDN) presenting at the Leerink Partners Conference 2025?
Who will represent ELDN at the Leerink Partners Global Healthcare Conference?
How can investors access ELDN's presentation at the Leerink Conference?
What type of presentation format will ELDN deliver at the Leerink Healthcare Conference?
